Skip to content

Canadian Research Initiative

Advancing bronchiectasis research, together

BXConnect—the Canadian Bronchiectasis and NTM Research Registry—connects patients, clinicians, and researchers to accelerate discoveries and improve outcomes for those living with non-CF bronchiectasis.

2,000

Target Participants

27

Years of Study

2

Active Trials

3+

Partner Cities

About the Registry

Building Canada’s most comprehensive bronchiectasis database

The Canadian Bronchiectasis and NTM Research Registry is a prospective observational study designed to collect comprehensive clinical data and quality of life assessments from patients with non-CF bronchiectasis and Nontuberculous Mycobacteria (NTM) infections.

Led by the University of Calgary in partnership with Insmed Incorporated and Trudell Medical International, this registry represents a pivotal moment in bronchiectasis research—coinciding with the first FDA-approved treatments entering development and growing pharmaceutical interest in clinical trial partnerships.

NCT06144996

ClinicalTrials.gov

2023 – 2050

Study Timeline

Conditions Studied

Non-CF Bronchiectasis

A chronic lung condition characterized by permanently damaged and widened airways, leading to mucus buildup and recurrent infections—unrelated to cystic fibrosis.

Nontuberculous Mycobacteria (NTM)

Infections caused by environmental bacteria that commonly affect individuals with bronchiectasis, often requiring specialized and prolonged treatment approaches.

Research & Collaboration

Driving discoveries through collaboration

Our registry facilitates partnerships between academic institutions, pharmaceutical companies, and healthcare providers to accelerate bronchiectasis research.

Clinical Trials

Two active clinical trials (Phase 2 and Phase 3) with multiple pharmaceutical companies approaching for partnership opportunities.

Learn more

Data Analysis

Comprehensive demographic and clinical parameter analysis, including hospitalization rates and exacerbation frequency tracking.

View methodology

Collaboration

Partner with leading institutions and pharmaceutical companies to advance bronchiectasis treatment development.

Partner with us

Breakthrough Moment

First FDA-approved bronchiectasis treatment in development

Brensocatib under Priority Review—a pivotal advancement for the bronchiectasis community.

Read More

Join the Registry

Your participation advances research

By joining our registry, you contribute to groundbreaking research that could lead to new treatments and better outcomes for thousands of patients.

Eligibility Criteria

Inclusion Criteria

  • Adults over the age of 18
  • Diagnosis of non-CF bronchiectasis
  • Diagnosis of Nontuberculous Mycobacteria (NTM)

Exclusion Criteria

  • Under the age of 18
  • Cystic fibrosis-related bronchiectasis

How to Enroll

1

Contact Our Team

Reach out to our research coordinators to express interest and ask questions.

2

Eligibility Review

Our team will review your medical history to confirm eligibility criteria.

3

Informed Consent

Review and sign the consent form after discussing the study with our team.

4

Begin Participation

Complete initial assessments and begin contributing to vital research.

Get in Touch

Ready to participate or collaborate?

Whether you’re a patient interested in enrollment, a healthcare provider seeking to refer patients, or a researcher exploring collaboration opportunities, we’d love to hear from you.

Location

University of Calgary Calgary, Alberta T2N 4N1, Canada

Phone

403-210-8945

Send us a message